Kazia Therapeutics Limited (KZIA)
After hours:
| Previous close | 0.2825 |
| Open | 0.2990 |
| Bid | 0.2710 x 100 |
| Ask | 0.2788 x 100 |
| Day's range | 0.2700 - 0.3100 |
| 52-week range | 0.1900 - 1.3900 |
| Volume | |
| Avg. volume | 847,156 |
| Market cap | 7.17M |
| Beta (5Y monthly) | 2.11 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.3600 |
| Earnings date | 27 Mar 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 2.01 |
PR NewswireKAZIA REPORTS SUCCESSFUL STAGE 1 COMPLETION OF THE EVT801 PHASE 1 CLINICAL TRIAL IN ADVANCED CANCER PATIENTS
Kazia Therapeutics Limited (NASDAQ: KZIA), a biotechnology company specialising in oncology, is pleased to announce that the Safety Review Team (SRT) of the EVT801 Phase 1 clinical trial has concluded that the primary and secondary objectives of stage 1 of the trial have successfully been met.
Insider Monkey11 Best ASX Stocks To Buy Now
In this piece, we will take a look at the 11 best ASX stocks to buy now. If you want to skip our introduction to the Australian stock market, then you can take a look at the 5 Best ASX Stocks To Buy Now. With a market capitalization of $1.5 trillion, the Australian stock exchange, […]
- PR Newswire
Kazia Therapeutics licenses paxalisib to Sovargen for intractable seizures in rare central nervous system diseases
Kazia Therapeutics Limited (NASDAQ: KZIA), a biotechnology company specialising in oncology, is pleased to announce that it has entered into an exclusive licensing agreement with Sovargen Co., Ltd, a biotechnology company specializing in central nervous system (CNS) diseases, to develop, manufacture and commercialise paxalisib as a potential treatment of intractable epilepsy in focal cortical dysplasia type 2 (FCD T2) and tuberous sclerosis complex (TSC) disease. The underlying cause of FCD T2 a
